Advanced search
Publication Cover
Future Oncology Volume 16, 2020 - Issue 15
Submit an article Journal homepage
5,738
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Real-World Treatment Duration in ALK-Positive Non-Small-Cell Lung Cancer Patients Receiving Brigatinib Through the Early Access Program

Huamao M Lin1 Millennium Pharmaceuticals, Inc.,Cambridge,MA02139,USACorrespondence[email protected]
View further author information
,
Xiaoyun Pan2 EMD Serono, Inc.,Billerica,MA01821,USAView further author information
,
Peijie Hou3 Regeneron Pharmaceuticals, Inc.,Tarrytown,NY10591,USAView further author information
,
Susan Allen1 Millennium Pharmaceuticals, Inc.,Cambridge,MA02139,USAView further author information
,
Pia Baumann1 Millennium Pharmaceuticals, Inc.,Cambridge,MA02139,USAView further author information
&
Maximilian J Hochmair4 Karl Landsteiner Institute of Lung Research & Pulmonary Oncology,Department of Respiratory & Critical Care Medicine,Krankenhaus Nord,Vienna,AustriaView further author information
Pages 1031-1041 | Received 23 Dec 2019, Accepted 20 Mar 2020, Published online: 27 Apr 2020

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

David Heredia, Feliciano Barrón, Andrés F. Cardona, Saul Campos, Jerónimo Rodriguez-Cid, Luis Martinez-Barrera, Jorge Alatorre, Miguel Ángel Salinas, Luis Lara-Mejia, Diana Flores-Estrada & Oscar Arrieta. (2021) Brigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP). Future Oncology 17:2, pages 169-181.
Read now

Articles from other publishers (6)

Mohammad Jahanzeb, Huamao M Lin, Yanyu Wu, Pingkuan Zhang, Magdaliz Gorritz, Catherine B McGuiness, Wei-Ti Huang, Kainan Sun, Chi-Chang Chen & D Ross Camidge. (2022) Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States. The Oncologist 27:9, pages 790-798.
Crossref
Renaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, Marie Wislez, Jacques Cadranel, Alexis Benjamin Cortot, Florian Guisier, Loïck Galland, Pascal Do, Roland Schott, Éric Dansin, Jennifer Arrondeau, Jean-Bernard Auliac, Margaux Geier & Christos Chouaïd. (2022) Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study. Cancers 14:7, pages 1751.
Crossref
Chaowei Ren, Ning Sun, Haixia Liu, Ying Kong, Renhong Sun, Xing Qiu, Jinju Chen, Yan Li, Jianshui Zhang, Yuedong Zhou, Hui Zhong, Qianqian Yin, Xiaoling Song, Xiaobao Yang & Biao Jiang. (2021) Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile. Journal of Medicinal Chemistry 64:13, pages 9152-9165.
Crossref
Sanjay Popat, Odd Terje Brustugun, Jacques Cadranel, Enriqueta Felip, Marina Chiara Garassino, Frank Griesinger, Åslaug Helland, Maximilian Hochmair, Maurice Pérol, Nawal Bent-Ennakhil, Christian Kruhl & Silvia Novello. (2021) Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer 157, pages 9-16.
Crossref
Maximilian Johannes Hochmair, Helmut Prosch, Dagmar Krenbek, Christoph Weinlinger, Hannah Fabikan & Arschang Valipour. (2020) Alectinib following brigatinib: an efficient sequence for the treatment of advanced anaplastic lymphoma kinase-positive lung cancer patients. Anti-Cancer Drugs 32:1, pages 105-110.
Crossref
Diego Kauffmann-Guerrero, Kathrin Kahnert & Rudolf M. Huber. (2020) Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer. Drugs 81:1, pages 87-100.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.